Trial Profile
A 26-week Randomised, Parallel Two-arm, Double-blind, Multi-centre, Multinational, Treat-to-target Trial Comparing Fixed Ratio Combination of Insulin Degludec and Liraglutide With Insulin Degludec in Subjects With Type 2 Diabetes
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin degludec/liraglutide (Primary) ; Insulin degludec
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms DUAL-II
- Sponsors Novo Nordisk
- 23 Jan 2019 According to a Novo Nordisk media release, Xultophy was approved by Health Canada in April 2018 based on data from the DUAL clinical development program.
- 05 Oct 2018 Results of a post-hoc analysis from DUAL I-V and VII studies, presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
- 05 Oct 2018 Results of post-hoc analysis of DUAL I, II. V and VII evaluating patients with an HbA1c more than 9% at baseline to determine the impact of IDegLira on their glycaemic control presented at the 54th Annual Meeting of the European Association for the Study of Diabetes